// App-Quantinova.ai

P3-10-03 : Etirinotecan pegol target-specific pharmacodynamic biomarkers in circulating tumor cells from patients with metastatic breast cancer in the phase 3 BEACON study

Researchers

Presenter

  • Perez EA

Principal Investigators

  • Caygill K

  • Hannah AL

  • Hoch UCortes JAwada A

  • OShaughnessy J

  • Twelves C

  • Rugo H

  • Im S-A

  • Anderes K

  • Davis DW

Medical Centers

  • University of California, San Francisco, CA

  • Consultant, Sebastopol, CAMayo Clinic, Jacksonville, FLVall dHebron University Hospital, Barcelona, Spain

  • ApoCell, Inc., Houston, TX

  • Baylor Sammons Cancer Ctr US Onc, Dallas, TX

  • Jules Bordet Institute, Bruxelles, Belgium

  • Seoul National University Hospital, Seoul, Korea

  • Nektar Therapeutics, San Francisco, CA

  • University of Leeds, St Jamess University Hospital, Leeds, United Kingdom

Locations

  • Spain

  • United Kingdom

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • ATP-binding cassette super-family G member 2

  • Peripheral blood mononuclear cell

  • Circulating tumor cells

  • Cluster of differentiation 45

  • Proliferation marker protein Ki-67

Drug/Treatment

  • etirinotecan pegol

Outcome

  • N/A

Study Design

  • pharmacodynamics

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved